OBJECTIVE: To document the management of and outcomes for patients receiving narcotic replacement and tapering with long-acting morphine preparations during pregnancy. DESIGN: A prospective cohort study over 18 months. SETTING: Northwestern Ontario. PARTICIPANTS: All 600 births at Meno Ya Win Health Centre in Sioux Lookout, Ont, from January 1, 2012, to June 30, 2013, including 166 narcotic-exposed pregnancies. INTERVENTION: Narcotic replacement and tapering of narcotic use with long-acting morphine preparations. MAIN OUTCOME MEASURES: Prenatal management of maternal narcotic use, incidence of neonatal abstinence syndrome, and other neonatal outcomes. RESULTS: The incidence of neonatal abstinence syndrome fell significantly to 18.1% of pregnancies exposed to narcotics (from 29.5% in a previous 2010 study, P = .003) among patients using narcotic replacement and tapering with long-acting morphine preparations. Neonatal outcomes were otherwise equivalent to those of the nonexposed pregnancies. CONCLUSION: In many patients, long-acting morphine preparations can be safely used and tapered in pregnancy, with a subsequent decrease in observed neonatal withdrawal symptoms.
OBJECTIVE: To document the management of and outcomes for patients receiving narcotic replacement and tapering with long-acting morphine preparations during pregnancy. DESIGN: A prospective cohort study over 18 months. SETTING: Northwestern Ontario. PARTICIPANTS: All 600 births at Meno Ya Win Health Centre in Sioux Lookout, Ont, from January 1, 2012, to June 30, 2013, including 166 narcotic-exposed pregnancies. INTERVENTION: Narcotic replacement and tapering of narcotic use with long-acting morphine preparations. MAIN OUTCOME MEASURES: Prenatal management of maternal narcotic use, incidence of neonatal abstinence syndrome, and other neonatal outcomes. RESULTS: The incidence of neonatal abstinence syndrome fell significantly to 18.1% of pregnancies exposed to narcotics (from 29.5% in a previous 2010 study, P = .003) among patients using narcotic replacement and tapering with long-acting morphine preparations. Neonatal outcomes were otherwise equivalent to those of the nonexposed pregnancies. CONCLUSION: In many patients, long-acting morphine preparations can be safely used and tapered in pregnancy, with a subsequent decrease in observed neonatal withdrawal symptoms.
Authors: Dinah Kanate; David Folk; Sharon Cirone; Janet Gordon; Mike Kirlew; Terri Veale; Natalie Bocking; Sara Rea; Len Kelly Journal: Can Fam Physician Date: 2015-02 Impact factor: 3.275
Authors: G Fischer; R Jagsch; H Eder; W Gombas; P Etzersdorfer; K Schmidl-Mohl; C Schatten; M Weninger; H N Aschauer Journal: Addiction Date: 1999-02 Impact factor: 6.526
Authors: Robert D Stewart; David B Nelson; Emily H Adhikari; Donald D McIntire; Scott W Roberts; Jodi S Dashe; Jeanne S Sheffield Journal: Am J Obstet Gynecol Date: 2013-05-29 Impact factor: 8.661
Authors: Constance Guille; Kelly S Barth; Julio Mateus; Jenna L McCauley; Kathleen T Brady Journal: Am J Psychiatry Date: 2017-03-01 Impact factor: 18.112
Authors: Mishka Terplan; Hollis J Laird; Dennis J Hand; Tricia E Wright; Ashish Premkumar; Caitlin E Martin; Marjorie C Meyer; Hendrée E Jones; Elizabeth E Krans Journal: Obstet Gynecol Date: 2018-05 Impact factor: 7.661
Authors: Stacey L Klaman; Krystyna Isaacs; Anne Leopold; Joseph Perpich; Susan Hayashi; Jeff Vender; Melinda Campopiano; Hendrée E Jones Journal: J Addict Med Date: 2017 May/Jun Impact factor: 3.702
Authors: Constance Guille; Annie N Simpson; Edie Douglas; Lisa Boyars; Kathryn Cristaldi; James McElligott; Donna Johnson; Kathleen Brady Journal: JAMA Netw Open Date: 2020-01-03